BAY98-7111 + Naproxen Sodium (Aleve, BAYH6689) + Diphenhydramine HCl + BAY98-7111
Phase 1Completed 0 watching 0 views this week💤 Quiet
30
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Therapeutic Equivalence
Conditions
Therapeutic Equivalence
Trial Timeline
Jan 1, 2012 → Mar 1, 2012
NCT ID
NCT01666678About BAY98-7111 + Naproxen Sodium (Aleve, BAYH6689) + Diphenhydramine HCl + BAY98-7111
BAY98-7111 + Naproxen Sodium (Aleve, BAYH6689) + Diphenhydramine HCl + BAY98-7111 is a phase 1 stage product being developed by Bayer for Therapeutic Equivalence. The current trial status is completed. This product is registered under clinical trial identifier NCT01666678. Target conditions include Therapeutic Equivalence.
Hype Score Breakdown
Clinical
10
Activity
5
Company
7
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01666678 | Phase 1 | Completed |
Competing Products
11 competing products in Therapeutic Equivalence
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) + Rivaroxaban (Xarelto, BAY59-7939) | Johnson & Johnson | Phase 1 | 33 |
| Remimazolam Tosilate for Injection + Remimazolam Tosilate for Injection | Jiangsu Hengrui Medicine | Approved | 85 |
| Amifostine + Carboplatin + Paclitaxel | AstraZeneca | Phase 2 | 52 |
| methylprednisolone + methylprednisolone | Pfizer | Phase 1 | 32 |
| methylprednisolone + methylprednisolone | Pfizer | Phase 1 | 32 |
| etynodiol diacetate + etynodiol diacetate | Pfizer | Phase 1 | 32 |
| methylprednisolone + methylprednisolone | Pfizer | Phase 1 | 32 |
| Fesoterodine + Fesoterodine + Fesoterodine + Fesoterodine + Fesoterodine + Fesoterodine | Pfizer | Phase 1 | 32 |
| Pravastatin + Pravastatin | Viatris | Phase 1 | 30 |
| Pravastatin + Pravastatin | Viatris | Phase 1 | 30 |
| Raxibacumab | Emergent BioSolutions | Phase 2/3 | 57 |